Achalasia Microcephaly

Achalasia–microcephaly is an extremely rare, likely inherited condition in which a child has achalasia (the food pipe does not relax and move food down normally) together with microcephaly (a head size much smaller than expected for age and sex). The achalasia causes coughing, choking, vomiting, trouble swallowing, poor weight gain, and chest infections from milk/food going the wrong way. The microcephaly is lifelong and can be mild or severe and may come with learning difficulties, seizures, movement problems, and speech delay. Only a small number of families have been reported worldwide, and several reports suggest autosomal recessive inheritance (both parents silently carry a changed gene). A few case reports also noted first-trimester exposure to the antimalarial mefloquine in one pregnancy, but this does not prove cause—only an association in a single case. There is no single “curative” pill; treatment focuses on (1) opening the lower esophageal sphincter to help swallowing and prevent aspiration and (2) early, sustained developmental care for the brain and body. orpha.netGenetic & Rare Diseases CenterNCBIAccessPediatricsPubMed+2PubMed+2

Achalasia–microcephaly is a very rare genetic condition. Children have two main medical problems at the same time:

1. Microcephaly — a head size that is smaller than normal for age and sex, which reflects a smaller brain and often leads to developmental delay and intellectual disability.

2. Achalasia — the food pipe (esophagus) does not move food properly, and the lower valve (lower esophageal sphincter) does not relax well. This makes swallowing hard, causes food and liquid to come back up, and can lead to coughing, vomiting, poor weight gain, and even food going into the lungs. Symptoms usually start in infancy or early childhood. orpha.netNCBI

Doctors have reported only a few families in the medical literature worldwide. In several families, the parents were related (consanguineous), and the pattern looks autosomal recessive (a child is affected when both parents carry the same rare faulty gene). The first family was described in the late 1970s, and fewer than a dozen cases were documented in early reviews. PubMedaccesspediatrics.mhmedical.com

Because AMS is so rare, experts use knowledge from three areas to guide care: descriptions of AMS families, general science about microcephaly, and general science about achalasia. Microcephaly is often genetic and is defined as a head circumference more than 2 standard deviations below the mean. Achalasia most often results from loss of the nerve cells that coordinate esophageal movement (myenteric neurons). WikipediaMayo Clinic

---

Other names

Doctors and databases may use several names for the same condition, including: “Achalasia–microcephaly syndrome,” “Achalasia microcephaly,” and “ACHALASIA-MICROCEPHALY SYNDROME.” Rare-disease registries list it under Orphanet ORPHA:929 and MONDO:0008699. orpha.netZFINEMBL-EBI

---

Types

Because there is no confirmed gene yet and very few patients, there are no formal medical subtypes of AMS. Still, it can help care teams to think about types in simple, practical ways:

1. By timing of microcephaly

   • Primary (congenital) microcephaly: small head noted at birth, suggesting prenatal brain growth problems.

   • Postnatal progressive microcephaly: head size normal or mildly small at birth, then falls off the curve in infancy. Both patterns are recognized in microcephaly science and may appear in AMS descriptions. Wikipedia

2. By achalasia pattern

   • Early-onset achalasia (infancy): feeding difficulty, choking/coughing with feeds, failure to thrive.

   • Childhood-onset achalasia (toddler/school age): trouble swallowing solids, regurgitation, chest/epigastric discomfort. (These are common achalasia presentations adapted to AMS.) Mayo Clinic

3. By family pattern

   • Familial/consanguineous: multiple siblings affected; suggests autosomal recessive inheritance.

   • Isolated (simplex): a single affected child in a family; still suspected autosomal recessive, but a new mutation is possible. PubMed

These groupings are only to guide thinking and do not imply different genes or different official diagnoses.

---

Causes

Important note: For AMS, a single confirmed gene has not been established. The list below explains likely or reported causes and contributors, based on AMS case reports and on well-studied biology of microcephaly and achalasia.

1. Autosomal recessive genetic change in an as-yet unknown gene that affects both brain development and esophageal nerve cells. This is strongly suspected from family patterns. PubMed

2. Parental consanguinity, which raises the chance that a child inherits the same rare gene change from both parents. (A contributor, not a cause by itself.) PubMed

3. Abnormal prenatal brain growth (disrupted neurogenesis)—the general mechanism behind congenital microcephaly. Frontiers

4. Loss or dysfunction of myenteric neurons in the esophagus, the usual mechanism in achalasia. Mayo Clinic

5. Autoimmune injury to esophageal nerves—a proposed mechanism in achalasia broadly (not proven specific to AMS). Mayo Clinic

6. Viral triggers that may damage esophageal nerves in achalasia (again, general achalasia science). Mayo Clinic

7. Neural crest/enteric nervous system developmental problems, which could logically link brain development with esophageal innervation (biological plausibility drawn from broader neurodevelopment literature). Frontiers

8. Primary microcephaly gene pathways (e.g., ASPM, WDR62) illustrate the kinds of neurogenesis processes that, if affected, can cause microcephaly; similar pathways might underlie AMS even if the exact AMS gene is unknown. BioMed CentralKarger

9. Reported prenatal mefloquine exposure in a single simplex AMS case—an association in one report, not a proven cause. NCBI

10. General genetic influences on familial achalasia (outside AMS) show heredity can play a role in esophageal motility disorders. Genetic & Rare Diseases Center

11. Association with rare achalasia syndromes (e.g., Allgrove/Triple-A) demonstrates that achalasia can be part of multisystem genetic disorders; this supports a genetic framework for AMS. PMC

12. Chromosomal or copy-number changes (detected by chromosomal microarray) can cause syndromic microcephaly in general; such testing is part of the AMS work-up even though specific AMS chromosomal defects haven’t been established. Genetic & Rare Diseases Center

13. Intrauterine infections (e.g., Zika, TORCH) are known causes of microcephaly broadly; they must be ruled out when evaluating a child for suspected AMS. Wikipedia

14. Nutritional compromise from severe achalasia can worsen postnatal brain growth and head-size trajectory (a secondary aggravating factor). (Inference based on achalasia causing failure to thrive.) orpha.net

15. Recurrent aspiration and lung illness can weaken overall health and growth, further worsening neurodevelopment (a secondary contributor). (AMS case descriptions note respiratory complications.) accesspediatrics.mhmedical.com

16. Mitochondrial or metabolic disorders are part of the differential for microcephaly; evaluating for them helps exclude look-alike conditions. (General microcephaly practice.) Frontiers

17. Multifactorial gene–environment interaction—a realistic model in rare neurodevelopmental syndromes when a single cause is not yet proven. (General neurodevelopment perspective.) Frontiers

18. Unknown de novo variant in a gene tied to both cortical development and enteric neurons—possible in isolated (simplex) families. (General genetics principle.) Genetic & Rare Diseases Center

19. Pathways shared with other primary microcephaly disorders (cell-cycle, centrosome, spindle function) provide biological clues to AMS even without a named gene yet. BioMed Central

20. Rare coincidental dual diagnoses (a child with an unrelated microcephaly disorder plus idiopathic achalasia). Clinically important to consider during work-up. (Differential diagnosis approach.) Mayo ClinicWikipedia

Symptoms

1. Small head size (microcephaly), often noticed at birth or soon after. Wikipedia

2. Developmental delay (motor and language milestones are late). orpha.net

3. Intellectual disability/learning difficulties, ranging from mild to severe. orpha.net

4. Feeding difficulty and trouble swallowing (dysphagia). orpha.net

5. Regurgitation and vomiting after feeds. orpha.net

6. Coughing or choking with feeds, sometimes worse when lying down. orpha.net

7. Failure to thrive or poor weight gain in infancy. orpha.net

8. Aspiration (food/liquid going into the airway) and recurrent chest infections. accesspediatrics.mhmedical.com

9. Chest or upper belly discomfort around meals (older children may report this). Mayo Clinic

10. Excess drooling and wet-sounding cough after feeds (signs of swallowing discoordination). orpha.net

11. Irritability with feeding; feeding times may be long and stressful. orpha.net

12. Sleep disturbance from nighttime cough or reflux/regurgitation. Mayo Clinic

13. Low muscle tone or coordination issues, which are common in many microcephaly disorders. Wikipedia

14. Possible facial or eye features reported in some summaries (e.g., strabismus, epicanthal folds); these vary by child and are not required for diagnosis. Medifind

15. Overall delayed growth compared with peers (weight/height curves may lag due to feeding problems). orpha.net

---

Diagnostic tests

A) Physical examination

1. Head-circumference measurement using a tape measure and growth charts. A value more than 2 standard deviations below average supports microcephaly. This should be tracked over time. Wikipedia

2. Whole-body growth check (weight, length/height, body mass index). Poor weight gain may point to feeding difficulty from achalasia. orpha.net

3. Developmental milestone assessment by history and observation (rolling, sitting, first words). This screens the impact of microcephaly on development. Wikipedia

4. Respiratory exam (listening for crackles/wheeze, watching work of breathing). This looks for aspiration-related lung problems. accesspediatrics.mhmedical.com

5. Neurologic exam (tone, reflexes, cranial nerves). Many microcephaly syndromes have neurologic signs that guide further testing. Wikipedia

B) Bedside/“manual” functional assessments

6. Clinical feeding and swallowing evaluation by a speech-language therapist. The clinician watches suck–swallow–breath coordination and signs of aspiration during small trial feeds. (Standard in pediatric dysphagia care.) orpha.net

7. Cranial-nerve focused oral-motor exam (gag, palate movement, tongue strength). This helps separate oropharyngeal issues from esophageal problems. (General neurology practice for dysphagia.) Mayo Clinic

8. Supervised small-volume swallow trials with different textures (liquid vs thicker fluids). Observing symptoms can guide need for imaging/manometry. (General dysphagia approach.) Mayo Clinic

9. Standardized developmental screening (e.g., validated checklists). This gives a baseline and guides therapies. (General pediatric practice for microcephaly.) Wikipedia

C) Laboratory and pathological tests

10. Complete blood count (CBC) and iron studies to check for anemia or infection from chronic aspiration. (Supportive work-up.) accesspediatrics.mhmedical.com

11. Metabolic panel and nutritional labs (electrolytes, albumin, vitamin levels) to assess impact of poor intake and regurgitation. (Supportive care.) orpha.net

12. Thyroid function tests if growth and development are particularly slow, because thyroid problems can also cause developmental delay (helps exclude other causes). (General pediatric work-up.) Wikipedia

13. TORCH/Zika testing when history suggests exposure, since these infections can cause microcephaly broadly and must be ruled out. Wikipedia

14. Chromosomal microarray to look for copy-number changes that cause syndromic microcephaly; this is standard first-tier genetic testing even if a specific AMS change is not known. Genetic & Rare Diseases Center

15. Whole-exome or whole-genome sequencing when array is non-diagnostic. This can find rare, recessive variants; knowledge from primary microcephaly genes shows how often neurogenesis genes are involved. (May help future counseling even if a novel AMS gene is found.) FrontiersBioMed Central

D) Electrodiagnostic tests

16. Esophageal high-resolution manometry — the key test for achalasia. It measures pressure waves in the esophagus and shows poor peristalsis and a non-relaxing lower sphincter. Mayo Clinic

17. Electroencephalogram (EEG) if there are spells concerning for seizures, which are seen in some microcephaly disorders (not required in every child, but used when indicated). (General microcephaly practice.) Wikipedia

E) Imaging and endoscopic tests

18. Barium swallow (esophagram) — an X-ray movie while the child swallows barium. In achalasia, the esophagus may be enlarged with a classic “narrowing” at the bottom. Mayo Clinic

19. Upper endoscopy (EGD) — a camera test to look inside the esophagus/stomach. It helps exclude other causes (strictures, eosinophilic esophagitis) and assess food retention. (General achalasia evaluation.) Mayo Clinic

20. Chest X-ray (or chest CT when needed) to look for lung changes from aspiration and for a very dilated esophagus (mega-esophagus) in advanced achalasia. accesspediatrics.mhmedical.com

21. Brain MRI to study brain size, structure, and any malformations that can occur with microcephaly; helpful for prognosis and therapy planning. (Microcephaly work-up.) Frontiers

22. Cranial ultrasound (in young infants with open fontanelle) as an early, bedside way to screen the brain before MRI. (Microcephaly work-up.) Wikipedia

23. Videofluoroscopic swallow study (VFSS) or fiberoptic endoscopic evaluation of swallowing (FEES) to directly see if swallows are safe and to guide feeding strategies. (Pediatric dysphagia standards.) Mayo Clinic

24. Timed emptying studies (such as timed barium esophagram) to measure how quickly the esophagus clears after interventions; useful for follow-up. (Achalasia care concept.) Mayo Clinic

Non-pharmacological treatments

(15 physiotherapy-type approaches are included; the rest cover mind–body, education, feeding, and assistive care. For each: Description • Purpose • Mechanism • Benefits)

1. Swallowing therapy (with a speech-language therapist)
   Description: Exercises, safe-swallow postures, and pacing during meals.
   Purpose: Reduce choking/aspiration, improve feeding safety.
   Mechanism: Trains oropharyngeal muscles and coordinates timing to match the slowed esophageal emptying.
   Benefits: Fewer coughing episodes, better confidence with eating, safer oral feeding. PMC

2. Texture-modified diet
   Description: Thicker liquids, soft/moist foods, and small bites.
   Purpose: Make food easier to move past the tight lower esophageal sphincter (LES).
   Mechanism: Viscosity and small bolus size reduce stasis and regurgitation.
   Benefits: Less vomiting and aspiration; better calorie intake. JNM Journal

3. Postural feeding strategies
   Description: Upright feeding, slow pace, remain upright ≥30–45 minutes afterward; older children can try sipping warm water before meals.
   Purpose: Use gravity and relaxation to facilitate transit.
   Mechanism: Upright posture lowers passive reflux; warmth can transiently reduce LES tone.
   Benefits: Less regurgitation and nighttime cough. PMC

4. Chest physiotherapy (airway clearance)
   Description: Percussion, positioning, and cough-assist techniques taught to caregivers.
   Purpose: Prevent and treat atelectasis and aspiration-related infections.
   Mechanism: Mobilizes secretions to keep lungs clear.
   Benefits: Fewer hospitalizations for pneumonia.

5. Physiotherapy for gross motor skills (PT #1)
   Description: Guided exercises for head control, sitting, crawling, standing.
   Purpose: Counter delayed motor milestones from microcephaly.
   Mechanism: Repetition strengthens motor pathways and muscles.
   Benefits: Better balance, mobility, and independence. CDCMayo Clinic

6. Occupational therapy (PT #2)
   Description: Fine-motor, hand-to-mouth training, self-care skills, adaptive utensils.
   Purpose: Improve daily living (feeding, dressing).
   Mechanism: Task-specific neuroplastic training.
   Benefits: Greater functional independence. Mayo Clinic

7. Speech and language therapy (PT #3)
   Description: Early communication support; augmentative/alternative communication if needed.
   Purpose: Improve understanding and expression.
   Mechanism: Builds language circuits via structured practice.
   Benefits: Better participation at home and school. CDC

8. Early intervention programs (PT #4)
   Description: Coordinated services from infancy (PT/OT/SLT, developmental educator).
   Purpose: Maximize developmental potential.
   Mechanism: High-frequency, play-based stimulation in neural “sensitive periods.”
   Benefits: Better cognitive and motor outcomes. CDC

9. Feeding therapy (PT #5)
   Description: Oral-motor desensitization, chewing practice, pacing, and cue-based feeding.
   Purpose: Improve oral intake safely.
   Mechanism: Gradual exposure and motor training.
   Benefits: Higher calorie intake with fewer aversions.

10. Sleep hygiene program (PT #6)
    Description: Fixed schedule, dark/quiet room, consistent bedtime routine.
    Purpose: Improve sleep, which supports brain development.
    Mechanism: Conditions circadian rhythm and reduces arousals.
    Benefits: Better daytime behavior and caregiver wellbeing.

11. Vision and hearing services (PT #7)
    Description: Vision therapy/low-vision aids; audiology support and devices when needed.
    Purpose: Optimize sensory inputs that support learning.
    Mechanism: Augments remaining function with devices/training.
    Benefits: Improved engagement and safety. Medscape

12. Nutritional counseling (PT #8)
    Description: Dietitian plans energy-dense meals; monitors growth.
    Purpose: Prevent failure to thrive and micronutrient deficiencies.
    Mechanism: Calorie/protein densification; reflux-aware meal timing.
    Benefits: Weight gain, stronger immunity.

13. Pulmonary hygiene and aspiration precautions (PT #9)
    Description: Oral care, suction availability, and safe-swallow plans at school/home.
    Purpose: Lower pneumonia risk.
    Mechanism: Reduces bacterial load and aspiration events.
    Benefits: Fewer infections.

14. Physiotherapy for posture and tone (PT #10)
    Description: Stretching, positioning, orthoses for spasticity/hypotonia.
    Purpose: Prevent contractures, improve seating and feeding posture.
    Mechanism: Muscle-tendon plasticity and biomechanical alignment.
    Benefits: Easier caregiving, better function.

15. Constraint-induced movement or task-specific training (PT #11)
    Description: Intensive, goal-directed upper-limb practice when one side lags.
    Purpose: Improve hand use for feeding and play.
    Mechanism: Drives cortical re-mapping.
    Benefits: Greater independence.

16. Hydrotherapy (PT #12)
    Description: Guided exercises in warm water.
    Purpose: Low-impact strengthening and relaxation.
    Mechanism: Buoyancy reduces load; warmth eases muscle tightness.
    Benefits: Better range of motion and enjoyment.

17. Gait training with assistive devices (PT #13)
    Description: Walkers, standing frames, or orthotics as needed.
    Purpose: Improve mobility and bone health.
    Mechanism: Weight-bearing stimulates bone and posture.
    Benefits: Participation and fitness gains.

18. Caregiver skills training (PT #14)
    Description: Hands-on teaching for feeding, transfers, airway care, seizure first-aid.
    Purpose: Safer home care and fewer emergencies.
    Mechanism: Builds confidence and competence.
    Benefits: Better outcomes with fewer hospital visits.

19. School-based individualized education plan (IEP) (PT #15 / Educational therapy)
    Description: Adjusted goals, extra time, therapy in school, AAC devices.
    Purpose: Access to learning.
    Mechanism: Accommodations plus special instruction.
    Benefits: Improved literacy, social inclusion. CDC

20. Mind–body: caregiver stress reduction
    Description: Brief daily breathing, mindfulness, or yoga for caregivers.
    Purpose: Reduce burnout and improve care quality.
    Mechanism: Lowers stress hormones; improves sleep.
    Benefits: More consistent, patient-centered care.

21. Mind–body: structured play and music therapy
    Description: Rhythmic movement, songs with actions.
    Purpose: Engage attention; support motor planning and language.
    Mechanism: Multisensory entrainment.
    Benefits: Joyful practice of developmental skills.

22. Feeding equipment
    Description: Slow-flow nipples, cut-out cups, angled spoons, high-chair with trunk support.
    Purpose: Safer oral intake.
    Mechanism: Controls bolus size and posture.
    Benefits: Less choking; better calories.

23. Immunization on schedule
    Description: Routine vaccines plus influenza and pneumococcal per local guidelines.
    Purpose: Prevent infections that worsen nutrition and lung health.
    Mechanism: Adaptive immune protection.
    Benefits: Fewer severe illnesses. (General pediatric standard of care.)

24. Home safety plan
    Description: Seizure plan; suction and pulse oximeter if advised; emergency numbers visible.
    Purpose: Rapid response to respiratory or seizure events.
    Mechanism: Preparedness.
    Benefits: Reduced risk and anxiety.

25. Genetic counseling (pre-conception/prenatal)
    Description: Family history review and discussion of options.
    Purpose: Understand recurrence risk in suspected recessive syndromes.
    Mechanism: Carrier and family risk assessment.
    Benefits: Informed family planning. PubMed+1

---

Drug treatments

Important safety note: Doses below are typical starting ranges from general pediatric/adult practice and achalasia literature; the exact dose, age limits, and timing must be set by your clinician based on weight, comorbidities, and local guidelines.

1. Nifedipine (calcium-channel blocker) — before meals
   Purpose: Temporarily relax LES to ease swallowing.
   Typical dose: Adults often 10 mg sublingual 10–30 minutes before meals (pediatric specialist dosing required).
   Mechanism: Smooth-muscle relaxation at LES.
   Side effects: Headache, hypotension, edema, flushing. PMC

2. Isosorbide dinitrate (nitrate) — before meals
   Purpose: Short-term LES relaxation for symptom relief.
   Typical dose: Adults ~5 mg sublingual before meals (specialist pediatric dosing).
   Mechanism: NO donor → LES smooth-muscle relaxation.
   Side effects: Headache, dizziness, hypotension. PMC

3. Sildenafil (PDE-5 inhibitor)
   Purpose: Alternative for LES relaxation when others fail.
   Dose: Adult 25–50 mg before meals; pediatric use off-label under specialist care.
   Mechanism: Increases cGMP → smooth-muscle relaxation.
   Side effects: Headache, flushing, reflux. JNM Journal

4. Botulinum toxin (endoscopic injection at LES)
   Purpose: Weakens LES muscle to improve passage.
   Dose: Commonly 80–100 U divided in quadrants (specialist procedure).
   Mechanism: Blocks acetylcholine release.
   Side effects: Chest pain, transient GERD; effect wanes over months. www.asge.org

5. Proton-pump inhibitor (e.g., omeprazole/pantoprazole)
   Purpose: Treat reflux esophagitis, especially after myotomy/POEM.
   Dose: Pediatric ~1–2 mg/kg/day divided; adults 20–40 mg daily.
   Mechanism: Irreversibly inhibits gastric H⁺/K⁺-ATPase.
   Side effects: Headache, diarrhea; long-term risks monitored. PMC

6. Prokinetic trial (e.g., metoclopramide)
   Purpose: Improve gastric emptying/reflux symptoms in selected cases.
   Dose: Pediatric ~0.1–0.2 mg/kg/dose up to QID; adults 5–10 mg QID (limited in achalasia itself).
   Mechanism: D2 antagonism ↑ GI motility.
   Side effects: Drowsiness, extrapyramidal effects—use with caution. JNM Journal

7. Levetiracetam (antiepileptic)
   Purpose: Control seizures related to microcephaly when present.
   Dose: Pediatric ~10–60 mg/kg/day in 2 doses; adults 500–1500 mg BID.
   Mechanism: SV2A modulation.
   Side effects: Somnolence, mood changes. Mayo Clinic

8. Valproate (antiepileptic; specialist only)
   Purpose: Broad-spectrum seizure control (not for pregnancy).
   Dose: Pediatric typically 10–60 mg/kg/day; adults variable.
   Mechanism: Increases GABA; multiple actions.
   Side effects: Weight gain, liver toxicity, teratogenicity—requires monitoring. Mayo Clinic

9. Baclofen (antispasticity, also reduces reflux events)
   Purpose: Treat spasticity and decrease transient LES relaxations.
   Dose: Pediatric specialist dosing; adults start 5–10 mg TID, titrate.
   Mechanism: GABA-B agonist.
   Side effects: Sedation, dizziness. JNM Journal

10. Melatonin (for sleep dysregulation)
    Purpose: Improve sleep quality in neurodevelopmental disorders.
    Dose: Pediatric 1–3 mg at bedtime; adults 2–5 mg (local guidance).
    Mechanism: Circadian signaling.
    Side effects: Morning drowsiness.

11. Inhaled bronchodilator (e.g., albuterol) for reactive wheeze
    Purpose: Ease bronchospasm during respiratory illnesses.
    Dose: Standard age-based inhaler/nebulizer dosing.
    Mechanism: β2-agonist smooth-muscle relaxation.
    Side effects: Tremor, tachycardia.

12. Antibiotics (illness-specific, not routine)
    Purpose: Treat aspiration pneumonia when diagnosed.
    Dose: Per local pediatric protocols.
    Mechanism: Eradicate lung pathogens.
    Side effects: GI upset, allergy.

13. Vitamin D (if deficient)
    Purpose: Bone health with limited mobility/feeding issues.
    Dose: Per labs and age; commonly 400–1000 IU/day in children, higher if deficient.
    Mechanism: Calcium balance and bone mineralization.
    Side effects: Rare hypercalcemia at high doses.

14. Iron (if iron-deficiency anemia)
    Purpose: Treat anemia that worsens fatigue/appetite.
    Dose: ~3 mg/kg/day elemental iron in children; adults 65 mg elemental 1–3×/day per guidance.
    Mechanism: Replaces iron stores.
    Side effects: Constipation, dark stools.

15. Acid suppressants/H2 blockers (e.g., famotidine) when PPIs not tolerated
    Purpose: Reduce acid exposure if reflux is significant.
    Dose: Pediatric 0.5–1 mg/kg/dose BID; adults 20–40 mg BID.
    Mechanism: H2 receptor blockade.
    Side effects: Headache; rare tolerance. JNM Journal

---

Dietary molecular supplements

(Use only with clinician/dietitian oversight; doses are generic starting points.)

1. Omega-3 (EPA/DHA) — 250–500 mg/day combined EPA+DHA (age-adjusted)
   Function/Mechanism: Anti-inflammatory; may support neurodevelopment and reduce airway inflammation.

2. Medium-chain triglyceride (MCT) oil — 5–15 mL/day titrated
   Function: Energy-dense calories absorbed with less effort; helpful in poor weight gain.

3. Whey protein or peptide formulas — per dietitian plan
   Function: High-quality protein to maintain growth and immunity.

4. Probiotics (e.g., Lactobacillus/Bifidobacterium mixes) — per product label
   Mechanism: Gut microbiome support; may reduce infections/antibiotic-associated diarrhea.

5. Vitamin D3 — per labs (often 400–1000 IU/day children; adults 800–2000 IU)
   Function: Bone and immune support.

6. Iron — only if deficient (dose as above)
   Function: Corrects anemia; supports neurocognition.

7. Zinc — 5–10 mg/day children (age-adjusted), 10–20 mg/day adults short-term
   Function: Enzyme and immune function; may improve appetite.

8. Magnesium glycinate — age-appropriate low dose at night
   Function: May aid sleep/constipation; muscle relaxation.

9. L-carnitine — specialist-guided
   Function: Mitochondrial energy support in undernourished states.

10. Coenzyme Q10 — specialist-guided
    Function: Antioxidant/mitochondrial cofactor; theoretical support in high oxidative stress.

(These supplements are adjuncts, not treatments for AMS itself; prioritize calories, protein, and safe swallowing.)

---

Regenerative / stem-cell drugs

What the evidence says (and why I won’t list unproven drugs):
There are no approved immune-booster, regenerative, or stem-cell drugs that treat achalasia–microcephaly syndrome or reverse primary microcephaly. Stem-cell infusions, “exosome shots,” or unregulated “gene therapy” sold online are unproven and may be dangerous. If you are interested in research options, ask your specialist about legitimate clinical trials (for example, trials that study therapies for achalasia procedures or neurodevelopmental rehabilitation), but do not start any “regenerative drug” without trial oversight. Safer, evidence-based ways to support immunity include vaccinations, good nutrition, sleep, and prompt treatment of infections. CDC

---

Procedures / surgeries

1. Peroral Endoscopic Myotomy (POEM)
   Procedure: An endoscopist tunnels within the esophageal wall from the mouth and cuts the inner circular muscle at the LES (and longer if spastic).
   Why: Definitive, minimally invasive option to relieve the outflow obstruction; often favored for type III achalasia and redo cases.
   Evidence: Multiple guidelines consider POEM comparable to laparoscopic Heller myotomy for type I/II and preferred for type III. PMCSAGESales.amegroups.org

2. Laparoscopic Heller Myotomy (with partial fundoplication)
   Procedure: Surgeons divide the LES muscle through small abdominal incisions and add a partial fundoplication to limit reflux.
   Why: Long track record; durable symptom relief.
   Evidence: Core option in ACG/ASGE guidance; fundoplication reduces post-myotomy reflux. PMCwww.asge.org

3. Endoscopic pneumatic dilation
   Procedure: A balloon is positioned at the LES and inflated to split muscle fibers.
   Why: Effective non-surgical option; may require repeat sessions.
   Evidence: Recommended in guidelines as initial or repeat therapy depending on type and center expertise. PMC

4. Endoscopic botulinum toxin injection
   Procedure: Botox is injected into LES quadrants.
   Why: Short-term option for frail patients or as a bridge to more definitive therapy.
   Evidence: Improves symptoms for months; often needs repeat. www.asge.org

5. Feeding tube (gastrostomy/jejunostomy) in selected cases
   Procedure: Tube placed into the stomach or small bowel for nutrition.
   Why: Protects the lungs and ensures growth if oral feeding is unsafe or insufficient.
   Evidence: Supportive nutrition is standard when aspiration risk or failure to thrive persists despite therapy. (General pediatric practice; team decision.)

---

Prevention strategies

1. Early diagnosis and referral to a center experienced in achalasia and pediatric swallowing disorders. Medscape

2. Safe-swallow plan written for home and school (texture, posture, pacing).

3. Vaccinations on schedule (including influenza) to reduce pneumonia risk.

4. Oral hygiene after meals; reduces bacterial load if aspiration occurs.

5. Upright feeding and sleep positioning (head elevated if reflux).

6. Avoid over-the-counter sedatives that impair swallow or breathing unless prescribed.

7. Home action plans for cough, fever, dehydration, and seizures.

8. Growth monitoring with a dietitian to prevent malnutrition.

9. Genetic counseling for families with a prior affected child (recessive risk discussion). PubMed

10. Pregnancy medication review with an obstetrician; avoid known teratogens and do not self-medicate in early pregnancy. (Note: mefloquine exposure was noted in one reported AMS case; this is an association, not proof of causation.) PubMed

---

When to see a doctor urgently

• Choking spells, blue lips, or breathing difficulty during or after feeds.

• High fever, wet cough, or fast breathing (possible aspiration pneumonia).

• Poor feeding, vomiting everything, or signs of dehydration.

• Rapid weight loss, no weight gain, or severe fatigue.

• Seizures, new weakness, or loss of developmental skills.

• Worsening heartburn/chest pain after a procedure. (These are standard red flags in achalasia/microcephaly care.) PMCCDC

---

What to eat and what to avoid

What to eat

• Moist, soft foods (well-cooked rice/porridge, mashed vegetables, yogurt, ripe banana, soft proteins like eggs/fish).

• Energy-dense options (add oil, nut butters if safe, or prescribed high-calorie formulas) to meet calorie needs in small volumes.

• Thicker liquids if thin liquids trigger coughing; use prescribed thickeners.

• Warm water sips before meals may help some people with LES relaxation.

• Small, frequent meals; slow pace, careful chewing.

What to avoid

• Dry, crumbly, stringy foods (dry bread, tough meats) that stick and trigger regurgitation.

• Very cold, carbonated, or very spicy/acidic foods if they worsen pain or reflux.

• Large late-evening meals; avoid lying flat for 45–60 minutes after eating. JNM Journal

---

Frequently asked questions (FAQ)

1) Is there a cure for AMS?
No single curative medicine exists. Care targets achalasia (to protect lungs and nutrition) and supports development for microcephaly. CDC

2) Can children with AMS eat by mouth?
Many can with careful planning (texture, posture, pacing). Some need procedures (POEM/Heller/dilation) or, rarely, a feeding tube for safety and growth. www.asge.orgPMC

3) Which procedure is “best”—POEM, Heller, or dilation?
All are effective. Choice depends on achalasia type, age, center expertise, and family preference; POEM is often favored in spastic (type III) disease. PMCSAGES

4) Will my child still have reflux after myotomy or POEM?
Reflux can occur, so acid-suppressing therapy and diet/lifestyle steps are common after these procedures. PMC

5) Can medicines alone control achalasia long-term?
Pills (nifedipine, nitrates) give short-term relief; definitive benefit usually comes from POEM, Heller, or dilation. PMC

6) Is microcephaly treatable?
Head size will not “catch up,” but early PT/OT/SLT and school supports can maximize abilities; seizures and other issues are treated individually. CDCMayo Clinic

7) Is AMS always genetic?
Most reports suggest a recessive pattern in some families; however, the exact genes are not yet well defined, and non-genetic factors may coexist in individual cases. PubMed+1

8) What about gene therapy or stem-cell therapy?
There is no approved gene or stem-cell therapy for AMS; avoid clinics offering unproven “regenerative” cures. Ask about clinical trials with your specialist. CDC

9) How do we prevent chest infections?
Safe-swallow plan, upright feeding, oral hygiene, airway clearance, and staying up-to-date on vaccines reduce risk. (Standard pediatric practice.)

10) Which specialists should be on our team?
Gastroenterologist, pediatric surgeon or interventional endoscopist (for achalasia); pediatric neurologist; rehab team (PT/OT/SLT); dietitian; pulmonologist; and developmental pediatrics. PMCCDC

11) Are there warning signs after POEM or Heller?
Severe chest pain, fever, black stools, or persistent vomiting warrant urgent care. Follow your center’s post-procedure plan. CGH Journal

12) Do children outgrow achalasia?
No. It is a motility disorder; symptoms improve with effective therapy and monitoring. PMC

13) Can AMS be detected before birth?
Microcephaly can sometimes be seen on late-pregnancy ultrasound; genetic counseling is recommended in families with prior affected children. World Health Organization

14) Does one reported mefloquine exposure mean the drug causes AMS?
No. It was one case report showing exposure—not proof of causation. PubMed

15) What outcomes should families expect?
Outcomes vary. Many children improve swallowing after definitive therapy and gain skills with early intervention; ongoing support is essential. PMCCDC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 01, 2025.

PDF Documents For This Disease Condition References